Preclinical safety of topically administered nanostructure lipid carriers (NLC) for wound healing application: biodistribution and toxicity studies
Vairo C (1), Collantes M (2), Quincoces G (2), Villullas S (3), Peñuelas I (4), Pastor M (3), Gil AG (5), Gainza E (3), Hernandez RM (6), Igartua M (6), Gainza G (7).
Re-activation of the healing process is a major challenge in the field of chronic wound treatment. For that purpose, lipid-nanoparticles, especially nanostructured lipid carriers (NLC), possess extremely useful characteristics such as biodegradability, biocompatibility and long-term stability, besides being suitable for drug delivery.
Moreover, they maintain wound moisture due to their occlusive properties, which have been associated with increased healing rates. In the light of above, NLC have been extensively used topically for wound healing; but to date, there are no safety-preclinical studies concerning such type of application
Thus, in this work, biodistribution studies were performed in rats with the NLC previously developed by our research group, using technetium-99m (99mTc-NLC) as radiomarker, topically administered on a wound. 99mTc-NLC remained on the wound for 24 h and systemic absorption was not observed after administration. In addition, toxicological studies were performed to assess NLC safety after topical administration.
The results obtained demonstrated that NLC were non-cytotoxic, non-sensitizing and non-irritant/corrosive. Overall, it might be concluded that developed NLC remained at the administration area, potentially exerting a local effect, and were safe after topical administration on wounds.
CITATION Int J Pharm. 2019 Oct 5;569:118484. doi: 10.1016/j.ijpharm.2019.118484. Epub 2019 Jun 28